πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

254 results for β€œAstraZeneca” Clear

  1. CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  2. CISPLATIN, GEMCITABINE, INFLIXIMAB, Rilvegostomig, IMFINZI 50 mg/mL concentrate for solution for infusion., DS-8201a, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Advanced HER2-expressing Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  3. CISPLATIN, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    First-line patients with advanced biliary tract cancers (BTC)

    phase 3 small molecule active

    1 trial

  4. CISPLATIN, TAGRISSO 40 mg film-coated tablets, Datopotamab deruxtecan, TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, PEMETREXED

    AstraZeneca AB

    Non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  5. CYCLOPHOSPHAMIDE, PACLITAXEL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, CAPECITABINE, EPIRUBICIN, IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE, CARBOPLATIN, INFLIXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, PEMBROLIZUMAB, Datopotamab deruxtecan, Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, DOXORUBICIN

    AstraZeneca AB

    Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  6. Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic lymphocytic leukemia

    phase 3 small molecule active

    1 trial

  7. Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib

    AstraZeneca AB

    Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer

    phase 3 small molecule active

    1 trial

  8. Capivasertib, Placebo for capivasertib film-coated tablet for oral use, ABIRATERONE ACETATE, Capivasertib

    AstraZeneca AB

    Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency

    phase 3 small molecule active

    1 trial

  9. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  10. DAPAGLIFLOZIN, Zibotentan + Dapagliflozin, Zibotentan + Dapagliflozin

    AstraZeneca AB

    Chronic Kidney Disease and High Proteinuria

    phase 3 small molecule active

    1 trial

  11. DOCETAXEL, Inflectra 100 mg powder for concentrate for solution for infusion, Mycofit, 250 mg, kapsuΕ‚ki twarde, DOCETAXEL, INFLIXIMAB, Remsima 100 mg powder for concentrate for solution for infusion, Ceralasertib, MYCOPHENOLATE MOFETIL, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer InfusionslΓΆsung, DOCETAXEL, MYCOPHENOLATE MOFETIL, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, PACLITAXEL, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, TOPOTECAN, AZD5335, MIRVETUXIMAB SORAVTANSINE

    AstraZeneca AB

    Advanced Platinum-resistant Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  13. DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  14. DURVALUMAB, Savolitinib, MYCOPHENOLATE MOFETIL, Sutent 12.5 mg hard capsules, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules, INFLIXIMAB, Sutent 25 mg hard capsules

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  15. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  16. Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

  17. Datopotamab deruxtecan, Rilvegostomig, MYCOPHENOLATE MOFETIL, INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC β‰₯ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  18. ERIBULIN MESYLATE, VINORELBINE, GEMCITABINE, CAPECITABINE, CAPECITABINE, Datopotamab deruxtecan

    AstraZeneca AB

    "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"

    phase 3 small molecule active

    1 trial

  19. Esomeprazole Magnesium, NEXIUM 10 mg gastro-resistant granules for oral suspension, sachet, Esomeprazole Magnesium

    AstraZeneca AB

    Erosive Esophagitis

    phase 3 small molecule active

    1 trial

  20. FIBRINOGEN, HUMAN, RIVAROXABAN , APIXABAN , ETAMSYLATE , TRANEXAMIC ACID , -, PROTAMINE , -, ERYTHROCYTES , AMINOMETHYLBENZOIC ACID , -, AMINOCAPROIC ACID , Ondexxya 200 mg powder for solution for infusion, EDOXABAN , -

    AstraZeneca AB

    Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

    phase 3 small molecule active

    1 trial

  21. Forxiga 10 mg film-coated tablets, Baxdrostat Placebo, Baxdrostat, Baxdrostat, Baxdrostat

    AstraZeneca AB

    Prevention of Heart failure

    phase 3 small molecule active

    1 trial

  22. GEMCITABINE, GEMCITABINE, INFLIXIMAB, DURVALUMAB, MYCOPHENOLATE MOFETIL, CISPLATIN

    AstraZeneca AB

    Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder

    phase 3 small molecule active

    1 trial

  23. GEMCITABINE, INFLIXIMAB, CISPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, Rilvegostomig

    AstraZeneca AB

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  24. Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources